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Background
Among patients with a proximal vessel occlusion in the anterior circulation, 60 to 80% 
of patients die within 90 days after stroke onset or do not regain functional indepen-
dence despite alteplase treatment. We evaluated rapid endovascular treatment in addi-
tion to standard care in patients with acute ischemic stroke with a small infarct core, a 
proximal intracranial arterial occlusion, and moderate-to-good collateral circulation.
Methods
We randomly assigned participants to receive standard care (control group) or standard 
care plus endovascular treatment with the use of available thrombectomy devices (inter-
vention group). Patients with a proximal intracranial occlusion in the anterior circula-
tion were included up to 12 hours after symptom onset. Patients with a large infarct 
core or poor collateral circulation on computed tomography (CT) and CT angiography 
were excluded. Workflow times were measured against predetermined targets. The 
primary outcome was the score on the modified Rankin scale (range, 0 [no symptoms] 
to 6 [death]) at 90 days. A proportional odds model was used to calculate the common 
odds ratio as a measure of the likelihood that the intervention would lead to lower 
scores on the modified Rankin scale than would control care (shift analysis).
Results
The trial was stopped early because of efficacy. At 22 centers worldwide, 316 partici-
pants were enrolled, of whom 238 received intravenous alteplase (120 in the interven-
tion group and 118 in the control group). In the intervention group, the median time 
from study CT of the head to first reperfusion was 84 minutes. The rate of functional 
independence (90-day modified Rankin score of 0 to 2) was increased with the interven-
tion (53.0%, vs. 29.3% in the control group; P<0.001). The primary outcome favored the 
intervention (common odds ratio, 2.6; 95% confidence interval, 1.7 to 3.8; P<0.001), and 
the intervention was associated with reduced mortality (10.4%, vs. 19.0% in the control 
group; P = 0.04). Symptomatic intracerebral hemorrhage occurred in 3.6% of partici-
pants in intervention group and 2.7% of participants in control group (P = 0.75).
Conclusions
Among patients with acute ischemic stroke with a proximal vessel occlusion, a small 
infarct core, and moderate-to-good collateral circulation, rapid endovascular treat-
ment improved functional outcomes and reduced mortality. (Funded by Covidien and 
others; ESCAPE ClinicalTrials.gov number, NCT01778335.)
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Ischemic stroke is a devastating condi-tion with a high burden of neurologic dis-ability and death. As a systemic treatment, 
intravenous alteplase has been shown to be better 
than conservative care.1,2 Among patients with a 
proximal vessel occlusion in the anterior circula-
tion, 60 to 80% of patients die within 90 days 
after stroke onset or do not regain functional in-
dependence despite alteplase treatment.3,4 The 
major reason for the limited efficacy of alteplase 
is the modest rate of early reperfusion among 
patients with a large-vessel occlusion.5,6
Local treatment of large-vessel occlusion be-
gan with intraarterial delivery of thrombolytic 
drugs.7 The Prolyse in Acute Cerebral Thrombo-
embolism (PROACT) II study was the first posi-
tive trial of endovascular treatment involving 
patients with angiographically visualized occlu-
sion of the middle cerebral artery.8 Unfortu-
nately, subsequent trials did not confirm the 
clinical benefit even with the addition of first-
generation thrombectomy devices.3,9,10 Key les-
sons learned from these previous trials are the 
need for proof of proximal vessel occlusion,11 
rapid and effective imaging methods to exclude 
patients with a large infarct core,12-14 an effi-
cient workflow to achieve fast recanalization,15,16 
and high reperfusion rates.17-19
Recent studies have shown the superiority of 
retrievable stents over the previous generation of 
thrombectomy devices.17,18 The recently reported 
Multicenter Randomized Clinical Trial of Endo-
vascular Treatment for Acute Ischemic Stroke in 
the Netherlands (MR CLEAN) used this technol-
ogy, and the results of that trial showed clinical 
benefit with endovascular treatment.4 The Endo-
vascular Treatment for Small Core and Anterior 
Circulation Proximal Occlusion with Emphasis on 
Minimizing CT to Recanalization Times (ESCAPE) 
trial was designed to test whether patients with 
acute ischemic stroke, who were selected on the 
basis of results of computed tomography (CT) and 
CT angiography (CTA), would benefit from rapid 
endovascular treatment involving contemporary 
endovascular techniques.20
Me thods
Trial Design
The ESCAPE trial was a multicenter, prospective, 
randomized, open-label, controlled trial with blind-
ed outcome evaluation (PROBE design).20 Partici-
pants were assigned, in a 1:1 ratio, to receive en-
dovascular treatment plus guideline-based care 
(intervention group) or guideline-based care alone 
(control group) (see the Methods section in the 
Supplementary Appendix, available with the full 
text of this article at NEJM.org). This academic-
investigator–initiated trial was designed to an-
swer a practical question regarding a patient with 
acute ischemic stroke who has just undergone 
neurovascular imaging with noncontrast CT and 
CTA: “Should this patient undergo endovascular 
thrombectomy?” (Fig. S3 in the Supplementary 
Appendix).
The trial was monitored by an independent data 
and safety monitoring board. The study funders, 
including Covidien, were not involved in the de-
sign or conduct of the study, the preparation or 
review of the protocol, the collection or analysis 
of the data, or the preparation or review of the 
manuscript. All the authors collected data, pro-
vided comments on the analysis, contributed to 
the writing of the manuscript, and were indepen-
dent of the sponsors. All the authors vouch for 
the accuracy and completeness of the data and 
data analyses and for the fidelity of this report to 
the study protocol, available at NEJM.org.
Sites were selected for participation after vis-
its by the principal investigators and documenta-
tion of fast treatment times and efficient work-
flow. The principal investigator at each site signed 
a formal letter stating a commitment to attempt to 
enroll consecutive patients who were eligible for 
the ESCAPE trial.21 The ethics board at each site 
approved the trial. In jurisdictions where it was 
permitted, the consent process was deferred when 
the participant lacked the capacity to provide con-
sent and a legally authorized representative was 
unavailable.
Randomization was performed with the use 
of a real-time, dynamic, Internet-based, random-
ized minimization procedure (minimal sufficient 
balance method)22 to achieve distribution balance 
with regard to age, sex, baseline National Insti-
tutes of Health Stroke Scale (NIHSS) score (range, 
0 to 42, with higher scores indicating greater 
stroke severity), site of arterial occlusion, baseline 
Alberta Stroke Program Early Computed Tomog-
raphy Score (ASPECTS), and status with respect 
to intravenous alteplase treatment. The ASPECTS 
scale is a 10-point scoring system to quantify early 
ischemic changes in the middle-cerebral-artery ter-
ritory, with a score of 10 indicating normal and 
1 point subtracted for each abnormal region (de-
tails are available at www.aspectsinstroke.com).23,24
The New England Journal of Medicine 
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Participants
Eligible participants were adults (no upper-age 
limit) with a disabling ischemic stroke who had 
been functioning independently in the commu-
nity (score on the Barthel Index [range, 0 to 100, 
with higher scores indicating a greater ability to 
complete activities of daily living] ≥90) before 
the stroke. Enrollment could occur up to 12 hours 
after the onset of stroke symptoms. Noncontrast 
CT and CTA (preferably multiphase) were per-
formed to identify participants with a small in-
farct core, an occluded proximal artery in the 
anterior circulation, and moderate-to-good col-
lateral circulation.14,25-28 Multiphase CTA is less 
vulnerable to patient motion than CT perfusion, 
requires no additional contrast, and allows for 
quick determination of collateral status12 (Fig. S2 
in the Supplementary Appendix). The use of mag-
netic resonance imaging for patient selection was 
discouraged. A small infarct core was defined as 
an ASPECTS of 6 to 10. Proximal artery occlusion 
in the anterior circulation was defined as occlu-
sion of the middle-cerebral-artery trunk and its 
immediate branches, with or without intracrani-
al occlusion of the internal carotid artery (Fig. S4 
in the Supplementary Appendix). Moderate-to-
good collateral circulation was defined as the 
filling of 50% or more of the middle-cerebral-
artery pial arterial circulation on CTA (preferably 
on multiphase CTA).
Imaging was performed at the endovascular 
center; for patients transferred from other hos-
pitals, imaging was repeated. Before and during 
screening, participants were treated with intra-
venous alteplase when clinically appropriate as 
part of standard care (Fig. S3 in the Supplemen-
tary Appendix). We did not keep a log of patients 
who were screened for the trial.29
Treatments
Participants in the intervention group underwent 
rapid endovascular treatment. A cerebral angio-
gram was obtained. The neurointerventionist used 
available thrombectomy devices to achieve reper-
fusion. The use of retrievable stents was recom-
mended. During thrombus retrieval, suction 
through a balloon guide catheter in the relevant 
internal carotid artery was also recommended. 
The control group received the current standard 
of care as described in the Canadian or local 
guidelines for the management of acute stroke30,31 
(see the Methods section in the Supplementary Ap-
pendix). Participants in both groups received intra-
venous alteplase within 4.5 hours after the onset 
of stroke symptoms if they met accepted local 
guidelines for intravenous alteplase treatment.
Weekly monitoring of imaging and treatment 
speed, with regular feedback to sites by telecon-
ference, ensured adherence to participant eligi-
bility criteria and workflow metrics. Guidance 
on rapid, effective endovascular treatment and 
high-quality imaging methods was provided. The 
target time from study noncontrast CT to groin 
puncture was 60 minutes or less and from study 
noncontrast CT to first reperfusion (defined as 
first reflow in the middle cerebral artery) was 
90 minutes or less. These aggressive targets were 
chosen to emphasize speed and ensure rapid im-
aging acquisition and interpretation, quick trans-
fer of patients to the angiography suite, and fast 
reperfusion. If there were clear patient-related 
factors (e.g., vessel tortuosity) or workflow factors 
(e.g., unavailability of the intervention team) that 
would prevent meeting the time targets, it was 
recommended that patients not be enrolled.
Clinical Assessments and Outcomes
All participants had standard assessments of de-
mographic characteristics, medical history, labo-
ratory values, and stroke severity (NIHSS score). 
Details of the assessments have been published 
previously20 and are also available in the study 
protocol. The primary outcome — the score on 
the modified Rankin scale at 90 days after ran-
domization — was assessed by trained personnel 
who were unaware of the treatment-group assign-
ments. The modified Rankin scale is a graded in-
terval scale (range, 0 [no symptoms] to 6 [death]) 
for the assessment of neurologic functional dis-
ability.32 Secondary and safety outcomes includ-
ed early recanalization and reperfusion, intracra-
nial hemorrhage, angiographic complications, 
neurologic disability at 90 days, and death. Inter-
pretation of the imaging was performed at an 
external core laboratory by personnel who were 
unaware of the treatment-group assignments (when 
they interpreted the CT images), clinical data, and 
outcomes. External, independent clinical monitors 
validated the clinical data.
Statistical Analysis
The trial was powered to detect a shift in the 
distribution of scores on the modified Rankin 
scale at 90 days between the intervention and 
control groups, with scores of 5 (bedbound with 
severe disability) and 6 (death) combined, with 
The New England Journal of Medicine 
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the assumption that the differential effect would 
lead to a common odds ratio (indicating the odds 
of improvement of 1 point on the modified Rankin 
scale) of 1.8. A total required sample of 500 par-
ticipants was anticipated. One formal interim 
analysis after the enrollment of 300 participants 
was planned. The stopping rule for efficacy was 
defined with the use of O’Brien–Fleming bound-
aries on the binary outcome of a modified Rankin 
score at 90 days of 0 to 2 versus 3 to 6.20 The pri-
mary analysis was unadjusted and was performed 
in the intention-to-treat population. P values of less 
than 0.05 were considered to indicate statistical 
significance, and all tests of hypotheses were two-
sided. No adjustments were made for multiple 
comparisons. Adjusted estimates of effect were 
calculated, with adjustment for age, sex, baseline 
NIHSS score, baseline ASPECTS, location of occlu-
sion (internal carotid artery plus middle cerebral 
artery vs. middle cerebral artery only), and status 
with respect to intravenous alteplase treatment (yes 
vs. no). The assessment of effect modification (het-
erogeneity of treatment effect) was performed with 
the inclusion of multiplicative interaction terms. All 
analyses were performed with the use of Stata soft-
ware, version 12.1 (StataCorp). Figures were drawn 
with the use of both Stata software, version 12.1, 
and R software (R Development Core Team 2014, 
www.r-project.org). Further details are provided in 
the statistical analysis plan (available at NEJM.org).
Table 1. Baseline Characteristics and Process Measures.*
Variable
Intervention 
(N = 165)
Control  
(N = 150)
Demographic characteristics
Age — yr
Median 71 70
Interquartile range 60–81 60–81
Female sex — no. (%)  86 (52.1)  79 (52.7)
White race — no. (%)† 144 (87.3) 131 (87.3)
Medical history — no. (%)
Hypertension 105 (63.6) 108 (72.0)
Diabetes mellitus  33 (20.0)  39 (26.0)
Atrial fibrillation  61 (37.0)  60 (40.0)
Clinical characteristics
NIHSS score‡
Median 16 17
Interquartile range 13–20 12–20
Systolic blood pressure at hospital arrival — mm Hg
Median 147 146
Interquartile range 131–159 125–169
Glucose level at hospital arrival — mmol/liter§
Median 6.6 6.7
Interquartile range 5.8–7.7 5.7–7.8
Imaging characteristics
ASPECTS on CT — median (interquartile range)¶ 9 (8–10) 9 (8–10)
Location of occlusion on CTA — no./total no. (%)‖
ICA with involvement of the M1 middle-cerebral-artery segment  45/163 (27.6)  39/147 (26.5)
M1 or all M2 middle-cerebral-artery segments 111/163 (68.1) 105/147 (71.4)
Single M2 middle-cerebral-artery segment  6/163 (3.7)  3/147 (2.0)
Ipsilateral cervical carotid occlusion — no. (%) 21 (12.7) 19 (12.7)
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R esult s
early termination of the study
An unplanned interim analysis was conducted after 
the release of the MR CLEAN results, which showed 
efficacy of endovascular therapy (see the Meth-
ods section in the Supplementary Appendix). The 
ESCAPE trial was stopped early on the advice of 
the data and safety monitoring board because the 
prespecified boundary for efficacy had been crossed.
patients
At 22 centers in Canada (11 centers), the United 
States (6), South Korea (3), Ireland (1), and the 
Table 1. (Continued.)
Variable
Intervention 
(N = 165)
Control  
(N = 150)
Process times — min**
Stroke onset to randomization
Median 169 172
Interquartile range 117–285 119–284
Stroke onset to study CT
Median 134 136
Interquartile range 77–247 76–238
Stroke onset to start of IV alteplase
Median 110 125
Interquartile range 80–142 89–183
Study CT to groin puncture
Median 51
Interquartile range 39–68
Study CT to first reperfusion††
Median 84
Interquartile range 65–115
Stroke onset to first reperfusion††
Median 241
Interquartile range 176–359
Treatment with IV alteplase — no. (%) 120 (72.7) 118 (78.7)
* The intervention group was assigned to endovascular treatment plus standard care, and the control group was as-
signed to standard care alone. CT denotes computed tomography, CTA CT angiography, ICA internal carotid artery, 
and IV intravenous.
† Race was self-reported.
‡ Scores on National Institutes of Health Stroke Scale (NIHSS) range from 0 to 42, with higher scores indicating more 
severe neurologic deficits.
§ To convert the values to milligrams per deciliter, divide by 0.05551.
¶ The Alberta Stroke Program Early Computed Tomography Score (ASPECTS) is an imaging measure of the extent of 
ischemic stroke. Scores ranges from 0 to 10, with higher scores indicating a smaller infarct core (details are available 
at www.aspectsinstroke.com).
‖ In one participant in the intervention group, the location of the occlusion on CTA was not determined by the core lab-
oratory. Occlusion of the ICA with involvement of the M1 middle-cerebral-artery segment could occur with or without 
involvement of the A1 anterior-cerebral-artery segment (see Fig. S4 in the Supplementary Appendix). The M1 middle-
cerebral-artery segment extends from the origin to the site of bifurcation or trifurcation (the anterior temporal artery 
is considered a branch of the M1 segment). The M2 middle-cerebral-artery segments extend from the site of bifurca-
tion or trifurcation to the origin of the cortical branches.
** For the time from stroke onset to the start of IV alteplase, data were missing for 1 patient in the intervention group. 
For the time from study CT to groin puncture, 161 patients were included in the analysis. For the time from study CT 
to first reperfusion and the time from stroke onset to first reperfusion, 145 patients were included in the analysis.
†† First reperfusion was defined as the first visualization of reflow in the middle cerebral artery, usually on deployment 
of a retrievable stent.
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United Kingdom (1), a total of 316 participants 
underwent randomization before the trial was 
stopped: 165 participants were assigned to the 
intervention group, 150 participants were as-
signed to the control group, and 1 participant 
was excluded owing to improper consent proce-
dures. The trial enrolled 1.44 participants per 
center per month from February 2013 through 
October 2014. One participant in the control 
group crossed over to receive endovascular treat-
ment. In the intervention group, 14 participants 
did not receive any interventional therapy. Four 
participants (1.3%) were lost to follow-up; missing 
data on outcomes in these participants were not 
imputed (Fig. S1 in the Supplementary Appendix).
Baseline characteristics were similar in the 
two treatment groups (Table 1, and Table S1 in 
the Supplementary Appendix). Imaging protocol 
violations, identified by personnel who inter-
preted the images at the core laboratory, occurred 
in 26 participants (8.3%): 11 of 308 participants 
in whom the ASPECTS could be evaluated (3.6%) 
had a score of less than 6 on the ASPECTS scale, 
20 of 315 participants (6.3%) had poor collateral 
circulation, and 14 of 315 participants (4.4%) 
had inappropriate target-vessel occlusion (some 
participants had >1 protocol violation). Collat-
eral circulation was assessed with the use of 
multiphase CTA in a majority of participants. A 
total of 56 participants (17.8%) were enrolled 
with deferral of consent procedures. Monitoring 
of appropriate source documentation materials 
(with regard to informed consent, inclusion and 
exclusion criteria, randomization information, de-
mographic characteristics, and assessments at 
baseline [NIHSS score and Barthel Index score] 
and at day 90 [modified Rankin score, NIHSS 
score, and Barthel Index score]) was completed 
for all randomly assigned participants.
primary outcome
Analysis of the primary end point showed a com-
mon odds ratio (indicating the odds of improve-
ment of 1 point on the modified Rankin scale) of 
2.6 (95% confidence interval [CI], 1.7 to 3.8) favor-
ing the intervention (P<0.001) (Fig. 1A and Table 2). 
The median 90-day modified Rankin score was 
2 in the intervention group and 4 in the control 
group (P<0.001). The proportion of patients with a 
modified Rankin score of 0 to 2 at 90 days was 
53.0% in the intervention group and 29.3% in the 
control group (rate ratio, 1.8; 95% CI, 1.4 to 2.4; 
P<0.001). Mortality at 90 days was 10.4% in the 
intervention group and 19.0% in the control 
group (rate ratio, 0.5; 95% CI, 0.3 to 1.0; P = 0.04) 
(Fig. S5 in the Supplementary Appendix). The 
rate of symptomatic intracerebral hemorrhage 
was 3.6% in the intervention group and 2.7% in 
the control group (rate ratio, 1.4; 95% CI, 0.4 to 
4.7; P = 0.75). Device-related or procedural com-
plications were observed in 18 patients: 4 had a 
Modified Rankin Scale Score
0 20 40 60 80 100
Patients (%)
B According to Status with Respect to IV Alteplase Treatment
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4320 1 5 6
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Figure 1. Scores on the Modified Rankin Scale at 90 Days in the Intention-
to-Treat Population.
Scores on the modified Rankin scale range from 0 to 6, with 0 indicating no 
symptoms, 1 no clinically significant disability, 2 slight disability, 3 moder-
ate disability, 4 moderately severe disability, 5 severe disability, and 6 death. 
Panel A shows the distribution of scores at 90 days in the intervention and 
control groups in the overall trial population. A significant difference be-
tween the intervention and control groups was noted in the overall distribu-
tion of scores (unadjusted common odds ratio, indicating the odds of im-
provement of 1 point on the modified Rankin scale, 2.6; 95% confidence 
interval, 1.7 to 3.8), favoring the intervention. Panel B shows the distribu-
tion of scores at 90 days in the intervention and control groups according 
to status with respect to intravenous (IV) alteplase treatment. In this analy-
sis, there was no evidence of heterogeneity of effect (P = 0.89 for interaction 
by the Wald test).
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serious adverse event and 14 had a nonserious 
adverse event (Table 3, and Table S2 in the Sup-
plementary Appendix).
secondary outcomes and subgroup analyses
Secondary clinical and imaging end points fa-
vored the intervention group. The rate of patients 
with a score on the Barthel Index of 95 to 100 at 
90 days was 57.7% in the intervention group ver-
sus 33.6% in the control group, the rate of patients 
with a 90-day NIHSS score of 0 to 2 was 51.6% 
versus 23.1%, and the median 90-day score on the 
EuroQoL Group 5-Dimension Self-Report Ques-
tionnaire (EQ-5D) visual-analogue scale (range, 
0 to 100, with higher scores indicating better 
quality of life) was 80 versus 65 (Table 2).
There was no evidence of heterogeneity of ef-
fect across any of the prespecified subgroups 
(defined according to age, sex, baseline NIHSS 
score, baseline ASPECTS, occlusion location, and 
status with respect to alteplase treatment) or ac-
cording to the presence or absence of cervical 
carotid occlusion. All variables showed a direc-
tion of effect in favor of the intervention (Fig. 2, 
and Fig. S6 in the Supplementary Appendix). How-
ever, the absolute proportion of good outcomes 
varied substantially according to subgroup (Fig. 
1B, and Fig. S7 in the Supplementary Appendix). 
Table 2. Primary and Secondary Efficacy Outcomes.
Outcome
Intervention 
(N = 165)
Control 
(N = 150)
Difference  
(95% CI)*
Effect  
Variable
Unadjusted Value 
(95% CI)
Adjusted Value 
(95% CI)†
Primary outcome: modified Rankin 
score at 90 days‡
Common  
odds ratio
2.6 (1.7–3.8) 3.1 (2.0–4.7)
Modified Rankin score of 0–2 at  
90 days — no./total no. (%)§
 87/164 (53.0) 43/147 (29.3) 23.8 (13.2–34.4) Rate ratio 1.8 (1.4–2.4) 1.7 (1.3–2.2)
NIHSS score of 0–2 at 90 days — 
no./total no. (%)
 79/153 (51.6) 31/134 (23.1) 28.4 (17.8–39.2) Rate ratio 2.2 (1.6–3.2) 2.1 (1.5–3.0)
Barthel Index score of 95–100 at 
90 days — no./total no. (%)¶
 94/163 (57.7) 49/146 (33.6) 24.1 (13.3–34.9) Rate ratio 1.7 (1.3–2.2) 1.7 (1.3–2.2)
TICI score of 2b or 3 at final angio-
gram — no./total no. (%)‖
113/156 (72.4)
Modified AOL score of 2 or 3 — 
no./total no. (%)**
43/138 (31.2)
NIHSS score at 24 hours — median 
(interquartile range)††
6 (3–14) 13 (6–18) Beta  
coefficient
4.0 (2.2–5.8) 4.1 (2.6–5.6)
NIHSS score at 90 days — median 
(interquartile range)††
2 (1–8)  8 (3–19) Beta  
coefficient
6.5 (3.2–9.8) 6.5 (3.5–9.6)
EQ-5D visual-analogue scale score 
at 90 days — median (inter-
quartile range)††‡‡
80 (60–90)  65 (50–80) Beta  
coefficient
 9.4 (3.5–15.2)  9.9 (3.8–16.0)
* Differences (intervention group − control group) are shown as percentage points.
† Adjusted estimates were calculated with the use of multiple regression analyses. Estimates were adjusted for age, sex, baseline NIHSS 
score, baseline ASPECTS, occlusion location, and status with respect to intravenous alteplase treatment, as prespecified in the protocol 
and statistical analysis plan.
‡ The primary analysis involved 164 participants in the intervention group and 147 participants in the control group. Scores on the modified 
Rankin scale of functional disability range from 0 (no symptoms) to 6 (death). The common odds ratio was estimated from an ordinal lo-
gistic-regression model and indicates the odds of improvement of 1 point on the modified Rankin scale, with a common odds ratio great-
er than 1 favoring the intervention. The proportional odds assumption was tested and found to be valid.
§ A modified Rankin score of 0 to 2 indicates functional independence.
¶ The Barthel Index is an ordinal scale for measuring performance of activities of daily living. Scores range from 0 to 100, with 0 indicating 
severe disability and 95 or 100 no disability that interferes with daily activities.
‖ A Thrombolysis in Cerebral Infarction (TICI) score of 2b or 3 indicates successful reperfusion (see Table S3 in the Supplementary Appendix).
** A modified Arterial Occlusive Lesion (AOL) score of 2 or 3 indicates partial or complete recanalization (see Table S3 in the Supplementary 
Appendix).
†† Treatment effect was estimated with the use of simple linear regression.
‡‡ The EuroQoL Group 5-Dimension Self-Report Questionnaire (EQ-5D) visual-analogue scale is a continuous scale measure of self-reported 
quality of life. Scores range from 0 to 100, with 0 indicating the worst possible quality of life and 100 the best possible quality of life.
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A total of 49 patients underwent randomization 
6 or more hours after stroke onset; in the analysis 
of a modified Rankin score of 0 to 2 at 90 days, 
the direction of effect favored the intervention in 
these patients (rate ratio, 1.7; 95% CI, 0.7 to 4.0), 
but the between-group difference was not sig-
nificant.
Of 165 participants assigned to the interven-
tion group, 151 (91.5%) underwent endovascular 
treatment, and 120 (72.7%) received intravenous 
alteplase. General anesthesia was used in 15 par-
ticipants (9.1%). Retrievable stents were used in 
130 of the 151 participants (86.1%) who under-
went an endovascular procedure; 100 of these 
130 participants (77.0%) received a Solitaire stent 
(Covidien). In the intervention group, the medi-
an time from symptom onset to first reperfusion 
was 241 minutes (interquartile range, 176 to 359), 
the median time from study CT to first reperfu-
sion was 84 minutes (interquartile range, 65 to 
115), and the median time from groin puncture 
to first reperfusion was 30 minutes (interquartile 
range, 18 to 46). Successful reperfusion (as de-
fined by a core-laboratory–adjudicated Throm-
bolysis in Cerebral Infarction [TICI] score of 2b 
or 3, indicating complete filling of the expected 
vascular territory) was observed in 113 of 156 
participants (72.4%) in the intervention group: 
79 of 112 participants (70.5%) who received intra-
venous alteplase and 34 of 44 participants (77%) 
who did not. (For details on the TICI scale, see 
Table 3 in the Supplementary Appendix.)
In the control group, follow-up CTA was per-
formed in 138 participants (median time from 
symptom onset to follow-up CTA, 425 minutes 
[interquartile range, 355 to 564]). Successful 
recanalization (as defined by a core-laboratory–
adjudicated modified Arterial Occlusive Lesion 
score of 2 or 3 on CTA, indicating partial or 
complete recanalization of the occluded artery) 
was observed in 43 of 138 participants (31.2%): 
41 of 110 (37.3%) who received intravenous al-
teplase and 2 of 28 (7%) who did not. (For details 
on the modified Arterial Occlusive Lesion scale, 
see Table S3 in the Supplementary Appendix.)
Discussion
We found that among participants with acute 
ischemic stroke with a small infarct core, a prox-
imal intracranial occlusion in the anterior circu-
lation, and moderate-to-good intracranial collat-
eral circulation, rapid endovascular treatment 
improved the clinical outcome and reduced mor-
tality. The trial confirms the benefit of endovascu-
lar treatment reported recently in the MR CLEAN 
trial.4
The ESCAPE trial attempted to deliver rapid 
endovascular therapy to patients who were se-
lected for inclusion on the basis of imaging. Post 
hoc analysis of the Interventional Management of 
Stroke (IMS) III trial and the Solitaire FR Throm-
bectomy for Acute Revascularization (STAR) 
trial showed that achieving faster reperfusion, as 
Table 3. Reported Serious Adverse Events.
Event
Intervention 
(N = 165)
Control  
(N = 150)
Difference  
(95% CI)*
Rate Ratio  
(95% CI)
Adjusted Rate Ratio  
(95% CI)†
Death — no./total no. (%) 17/164 (10.4) 28/147 (19.0) 8.6 (0.8 to 16.6) 0.5 (0.3 to 1.0) 0.5 (0.3 to 0.8)
Large or malignant middle-cerebral-  
artery stroke — no. (%)‡
8 (4.8) 16 (10.7) 5.8 (0.1 to 11.7) 0.5 (0.2 to 1.0) 0.3 (0.1 to 0.7)
Symptomatic intracerebral hemorrhage 
— no. (%)‡§
6 (3.6) 4 (2.7) 1.0 (−2.9 to 4.8) 1.4 (0.4 to 4.7) 1.2 (0.3 to 4.6)
Hematoma at access site — no. (%)¶ 3 (1.8) 0
Perforation of the middle cerebral  
artery — no. (%)
1 (0.6) 0
* Differences (intervention group − control group) are shown as percentage points.
† Adjusted estimates were calculated with the use of multiple regression analyses. Estimates were adjusted for age, sex, baseline NIHSS score, 
baseline ASPECTS, occlusion location, and status with respect to intravenous alteplase treatment, as prespecified in the protocol and statis-
tical analysis plan.
‡ Two hemicraniectomy procedures were performed. The indications for hemicraniectomy were malignant middle-cerebral-artery ischemic stroke 
(one patient in the control group) and symptomatic intracerebral hemorrhage (one patient in the intervention group).
§ Symptomatic intracerebral hemorrhage was clinically determined at the study site.
¶ Hematoma occurred in two participants at the site of groin puncture. Neck hematoma occurred in the single participant in whom direct carotid 
access was used, after femoral access was unsuccessful.
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compared with slower reperfusion, was associated 
with a better clinical outcome.16,33 The ESCAPE 
trial achieved shorter interval times than those 
seen in past trials, with a median time from 
study noncontrast CT to first reperfusion of 84 
minutes. A prespecified efficiency target for the 
time from noncontrast CT to reperfusion en-
couraged fast image acquisition and interpreta-
tion and fast decision making.16,34-37 Critical to 
the achievement of rapid treatment was parallel 
decision making and action. For example, partici-
pants in the intervention group underwent groin 
puncture while alteplase was being infused, and 
complete reperfusion was achieved in some par-
ticipants before the alteplase infusion was fin-
ished. The primary emphasis was on achieving 
early reperfusion.15,16,34,35
Imaging-related selection criteria focused on 
the population with a small infarct core at base-
line, which was defined by both modest early 
ischemic change on noncontrast CT and moder-
ate-to-good collateral circulation distal to the 
occlusion.26 A new technique of collateral assess-
ment, multiphase CTA, was used in a majority of 
patients (Fig. S2 in the Supplementary Appendix).12 
This imaging approach resulted in a low number 
of imaging protocol violations and enabled the 
meeting of workflow time targets.
There was no evidence of heterogeneity of 
treatment effect across prespecified subgroups. 
2 4 6 8 10
Intervention BetterControl Better
Age
>80 yr
≤80 yr
ASPECTS
8–10
<8
Cervical carotid occlusion
Yes
No
IV alteplase
Received
Not received
NIHSS score at baseline
6–19
>19
Location of occlusion
ICA with involvement of the M1 MCA
segment
M1 MCA segment or all M2 MCA
segments
Time from stroke onset to randomization
≤180 min
>180 min
Sex
Male
Female
Common Odds Ratio (95% CI)Variable
3.0 (1.3–6.8)
2.5 (1.4–4.5)
2.6 (1.5–4.4)
2.5 (1.4–4.5)
2.6 (1.5–4.5)
2.7 (1.7–4.4)
2.6 (1.2–5.9)
2.4 (1.1–5.3)
2.6 (1.6–4.2)
2.6 (1.1–5.9)
2.5 (1.6–4.0)
2.2 (1.4–3.3)
   9.6 (2.6–35.5)
2.7 (1.0–7.2)
2.6 (1.7–4.1)
0
2.7 (1.7–4.3)
Figure 2. Subgroup Analyses.
A forest plot shows that the difference in the primary clinical outcome (common odds ratio indicating the odds of 
improvement of one point on the modified Rankin scale at 90 days, analyzed with the use of ordinal logistic regres-
sion) favored the intervention group across all prespecified subgroups. The thresholds for age and National Insti-
tutes of Health Stroke Scale (NIHSS) score (range, 0 to 42, with higher scores indicating more severe neurologic 
deficits) were chosen at the 75th percentile, and the threshold for time from stroke onset to randomization was chosen 
just above the median. The threshold for the Alberta Stroke Program Early Computed Tomography Score (ASPECTS; 
range, 0 to 10, with higher scores indicating a smaller infarct core) was prespecified. For cervical carotid occlusion, 
P = 0.049 for interaction by the Wald test. Other P values were greater than 0.10 for interaction. ICA denotes internal 
carotid artery, and MCA middle cerebral artery.
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Endovascular treatment appeared to benefit all 
ages (the oldest person enrolled in the trial was 
93 years of age), both sexes, patients with moder-
ate strokes and those with severe strokes, patients 
who received intravenous alteplase and those 
who did not, and patients with and those with-
out occlusion in the internal carotid artery (Fig. 
2, and Fig. S6 in the Supplementary Appendix). 
Although eligibility criteria allowed enrollment 
up to 12 hours after symptom onset, the median 
time from symptom onset to first reperfusion was 
241 minutes. A total of 49 participants (15.5%) 
underwent randomization 6 or more hours after 
symptom onset, and the study was not powered 
to assess endovascular therapy among patients 
presenting 6 to 12 hours after symptom onset.
The incidence of asymptomatic hemorrhagic 
infarction was greater in the intervention group 
than in the control group (Table S2 in the Sup-
plementary Appendix), possibly owing to early 
reperfusion.38 The rate of more serious paren-
chymal hematomas or symptomatic hemorrhage 
was not higher in the intervention group than in 
the control group. Device-related or procedural 
complications were uncommon.
MR CLEAN and the ESCAPE trial showed 
benefit and low complication rates with endo-
vascular treatment that was performed predomi-
nantly with retrievable stents. Factors that dis-
tinguish the ESCAPE trial from MR CLEAN and 
prior trials of endovascular treatment for stroke 
include the use of imaging to exclude partici-
pants with a large infarct core and poor collat-
eral circulation, a shorter interval from symptom 
onset to treatment initiation, a low rate of gen-
eral anesthesia (9% in the ESCAPE trial vs. 38% 
in MR CLEAN), and a higher rate of successful 
reperfusion (TICI score of 2b or 3). The longer 
time from alteplase administration to randomiza-
tion (approximately 114 minutes) in MR CLEAN 
indicated that most patients underwent random-
ization after the alteplase infusion was com-
pleted.4 These differences may account for the 
higher proportions of good outcomes and the 
larger effect size observed in the ESCAPE trial.
There are limitations of our study. First, we 
purposefully did not require screening logs 
(which tend to yield poor-quality data) and can-
not provide an estimate of how many patients 
were ineligible on the basis of imaging criteria. 
Second, a majority of participants were enrolled 
at selected endovascular centers that are capable 
of implementing efficient workflow and imag-
ing processes. This level of efficiency and exper-
tise is not currently widespread, which limits the 
immediate generalizability of our results. Although 
the time targets used in our trial may appear 
daunting, the history of intervention for acute 
coronary syndromes suggests that such efficiency 
in workflow is widely attainable.35,39,40
In conclusion, the ESCAPE trial, in which fast 
and efficient workflow, innovative imaging, and 
effective thrombectomy devices were used, pro-
vides evidence of the benefit of endovascular treat-
ment in patients with moderate-to-severe ische-
mic stroke.
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